RecruitingNCT07127926

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD

Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic Graft Versus Host Disease

Sponsor

M.D. Anderson Cancer Center

Enrollment

8 participants

Start Date

Feb 9, 2026

Study Type

OBSERVATIONAL

Conditions

Chronic Graft Versus Host Disease

Summary

The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).

Eligibility

Min Age: 18 Years

Inclusion Criteria1

Male and female subjects ≥ 18 years of age with allogeneic HSCT

Exclusion Criteria2

Receiving an investigational GVHD treatment within 28 days of study entry; (2) active acute GVHD; and (3) taking any medication known to be CYP3A4 inducers.
Pregnancy is an exclusion criterion for stem cell transplant. Pregnant women are not included in this study. Non-viable neonates will not be included in this study. Patients with cognitive impairments will not be included in this study. Patients aged less than 18 years old will not be included.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.